Objectives. Quetiapine, a benzothiazepine derivative, is an atypical antipsychotic with confirmed efficacy in the treatment of schizophrenia and bipolar disorder.
Review. Atypical neuroleptics may be the cause of the metabolic syndrome including obesity, glucose intolerance, hyperinsulinism, and serum lipid disturbances. In contradistinction to olanzapine and clozapine, quetiapine aggravates the metabolic syndrome constituents to a small degree only. Both the clozapine and olanzapine treatment is associated with the highest riskfor the metabolic syndrome incidence and subsequent cardiac disease. Quetiapine generally shows low to moderate levels of mean weight gain, as well as of blood glucose, triglicerides, and cholesterol concentrations.
Conclusions. Quetiapine seems to be an effective neuroleptic in the treatment ofpsychotic disorders in patients at riskfor atherosclerosis and cardiac disease.